Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "When the Anticancer Strategies Modulating Oxidative Stress Meet Nanomedicine: New Perspectives"
A special issue of Antioxidants (ISSN 2076-3921).
Deadline for manuscript submissions: closed (31 January 2020).
Interests: lipid peroxidation and cancer; chemoresistance and oxidative stress; nanomedicine to overcome chemoresistance
Although contradictory findings have been reported, the link between oxidative stress and tumours has become more and more evident in the last decades. Cancer cells exhibit elevated reactive oxygen species (ROS) levels, which can contribute, with different mechanisms, to the malignant transformation and progression of tumours. ROS scavenging compounds have been used in chemoprevention and at the early stage of treating tumours. However, very conflicting results have been obtained, so the use of antioxidants in cancer prevention needs to be carefully evaluated. On the other hand, the induction of oxidative stress can be toxic to cancer cells, potentially inducing apoptotic cell death. Thus, strategies with the goal of increasing the ROS level, directly, with prooxidant drugs (e.g. doxorubicin, menadione), or indirectly, by lowering the cellular antioxidant defences, have been used for effective cancer therapies.
Advances in the developing field of nanomedicine can further expand the possibilities of redox-anticancer treatments. Indeed, the use of nanoparticles (NPs) offers many advantages as drug carrier system, by improving the solubility of poorly water-soluble drugs, increasing drug half-life, improving bioavailability and diminishing the drug metabolism. Both antioxidant and pro-oxidant NPs (containing compounds that can reduce or enhance oxidative stress, respectively), as well as redox-sensitive NPs (in most cases containing disulfide bonds to achieve a stimuli-responsive drug release) have been investigated in cancer therapy. Moreover NPs per se can be redox active (e.g. cerium oxide/nanoceria), thus expanding the potential for their therapeutic use.
This Special Issue welcomes original research and reviews of literature concerning tumour chemoprevention and cancer progression studies of redox nanosystems, such as NPs per se redox active or containing conventional chemotherapic medicines, new alternative compounds, molecularly targeted cancer drugs, or nucleic acids with both antioxidant or pro-oxidant properties, as well as redox stimulus-responsive nanocarriers.
Dr. Stefania Pizzimenti
Dr. Monica Argenziano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Reactive oxygen species (ROS)
- Glutathione (GSH)
- Nuclear factor erythroid 2-related factor 2 (Nrf2)
- Redox signalling pathways
- Tumour progression
- Redox-sensitive nanoparticles